英国の心房細動デバイス市場は、2021年の7億610万ドルから2031年までに206億3900万ドルを超え、今後数年間、つまり2021年から2031年のCAGRは11.3％と予想されます。
目次
Contents
1. Executive Summary
2. U.K. Atrial Fibrillation Devices Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. U.K. Atrial Fibrillation Devices Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. U.K. Atrial Fibrillation Devices Market
11.1. Market Size & forecast, 2020A-2031F
11.1.1. By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
11.1.2. By Volume (Million Units) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12. U.K. Atrial Fibrillation Devices Market: Market Segmentation
12.1. By Regions
12.1.1. England, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.2. Northern Ireland, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.3. Scotland, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.4. Wales, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2. By Device Type: Market Share (2020-2031F)
12.2.1. Diagnostic and Monitoring Devices, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.2. Therapeutic and Surgical Devices, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3. By Disorder Type: Market Share (2020-2031F)
12.3.1. Paroxysmal Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.2. Persistent Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.3. Permanent Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.4. Others Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4. By End-User: Market Share (2020-2031F)
12.4.1. Hospitals, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.2. Cardiac Labs, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.3. Ambulatory Surgical Centers, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.4. Others, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13. Company Profile
13.1. Abbott,
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Boston Scientific Corporation,
13.3. Biotronik,
13.4. Cardinal Health,
13.5. GEHealthcare,
13.6. Medtronic Plc,
13.7. Siemens Healthineers AG,
13.8. W. L. Gore & Associates, Inc.,
13.9. Hansen Medical Inc,
13.10. Cardio focus.
13.11. Other Prominent Players
14. Consultant Recommendation
The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
